Omnicell (NASDAQ:OMCL) had its price objective reduced by Craig Hallum from $102.00 to $85.00 in a report issued on Wednesday morning, The Fly reports. They currently have a buy rating on the stock.

Several other analysts have also issued reports on OMCL. Cantor Fitzgerald boosted their price objective on shares of Omnicell from $85.00 to $90.00 and gave the company an overweight rating in a report on Wednesday. BidaskClub lowered shares of Omnicell from a hold rating to a sell rating in a report on Wednesday, July 8th. Benchmark reduced their price objective on shares of Omnicell from $96.00 to $82.00 and set a buy rating on the stock in a report on Friday, May 8th. Piper Sandler reduced their price objective on shares of Omnicell from $76.00 to $70.00 and set a neutral rating on the stock in a report on Wednesday. Finally, ValuEngine lowered shares of Omnicell from a buy rating to a hold rating in a report on Friday, April 17th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $85.50.

NASDAQ OMCL opened at $70.29 on Wednesday. Omnicell has a 52 week low of $54.24 and a 52 week high of $94.85. The business’s fifty day simple moving average is $67.18 and its 200-day simple moving average is $72.69. The firm has a market cap of $3.00 billion, a PE ratio of 62.20, a P/E/G ratio of 2.82 and a beta of 1.03.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Tuesday, July 28th. The company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.23 by $0.14. Omnicell had a return on equity of 9.21% and a net margin of 5.42%. The business had revenue of $199.62 million for the quarter, compared to analyst estimates of $182.16 million. During the same quarter in the previous year, the firm earned $0.67 EPS. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. As a group, equities research analysts expect that Omnicell will post 1.68 earnings per share for the current fiscal year.

In other Omnicell news, EVP Scott Peter Seidelmann sold 2,125 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $67.70, for a total transaction of $143,862.50. Following the sale, the executive vice president now directly owns 33,385 shares in the company, valued at $2,260,164.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Randall A. Lipps sold 3,718 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $75.15, for a total transaction of $279,407.70. Following the sale, the chief executive officer now owns 152,116 shares in the company, valued at $11,431,517.40. The disclosure for this sale can be found here. 2.63% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the company. Conestoga Capital Advisors LLC grew its position in shares of Omnicell by 5.6% during the first quarter. Conestoga Capital Advisors LLC now owns 1,665,760 shares of the company’s stock worth $109,241,000 after buying an additional 88,016 shares in the last quarter. State Street Corp grew its position in shares of Omnicell by 8.1% during the first quarter. State Street Corp now owns 1,303,978 shares of the company’s stock worth $85,515,000 after buying an additional 97,154 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Omnicell by 62.3% during the first quarter. Bank of New York Mellon Corp now owns 877,992 shares of the company’s stock worth $57,578,000 after buying an additional 337,035 shares in the last quarter. Waddell & Reed Financial Inc. grew its position in shares of Omnicell by 16.6% during the first quarter. Waddell & Reed Financial Inc. now owns 637,803 shares of the company’s stock worth $41,827,000 after buying an additional 90,934 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Omnicell by 6.6% during the first quarter. Geode Capital Management LLC now owns 611,079 shares of the company’s stock worth $40,074,000 after buying an additional 37,756 shares in the last quarter. 95.79% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Featured Article: Understanding the Price to Earnings Ratio (PE)

The Fly

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.